Results 1 to 10 of about 203,970 (332)

Interferon Alpha Association with Neuromyelitis Optica [PDF]

Clinical and Developmental Immunology, 2013
Interferon-alpha (IFN-α) has immunoregulatory functions in autoimmune inflammatory diseases. The goal of this study was to determine occurrence and clinical consequences of IFN-αin neuromyelitis optica (NMO) patients. Thirty-six NMO and 41 multiple sclerosis (MS) patients from a population-based retrospective case series were included.
Nasrin Asgari, Anne Voss, Troels Steenstrup, Kirsten Ohm Kyvik, Egon Stenager, Soeren Thue Lillevang   +5 more
openaire   +5 more sources

Interferon Alpha in Systemic Lupus Erythematosus [PDF]

Journal of Biomedicine and Biotechnology, 2010
The pleiotropic cytokine interferon alpha is involved in multiple aspects of lupus etiology and pathogenesis. Interferon alpha is important under normal circumstances for antiviral responses and immune activation.
Clark, Daniel N., Niewold, Timothy B., Poole, Brian D., Salloum, Rafah   +3 more
core   +6 more sources

The treatment of hepatitis C: history, presence and future [PDF]

, 2004
The treatment of chronic hepatitis C has made remarkable progress over the past two decades. For interferon-alpha monotherapy, sustained virological response rates were between 2 and 9% in genotype 1 and between 16 and 23% in genotypes ...
Knegt, R.J. (Robert) de, Orlent, H. (Hans), Schalm, S.W. (Solko), Veldt, B.J. (Bart), Vrolijk, J.M. (Jan)   +4 more
core   +10 more sources

Interferon‐alpha in lupus psychosis [PDF]

Arthritis & Rheumatism, 1992
AbstractObjective. Since the level of interferon‐α (IFNα) is increased in the sera of patients with active systemic lupus erythematosus (SLE) and is detectable in the cerebrospinal fluid (CSF) of some SLE patients with neuropsychiatric manifestations, we investigated the contribution of IFNα to the pathogenesis of the neuropsychiatric manifestations of
Shunsei Hirohata, Tetsuya Ogino, Shunichi Shiozawa, Yasuo Kuroki, Mitsunori Kim   +4 more
openaire   +2 more sources

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C [PDF]

, 2000
Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more efficacious than IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C and patients with IFN-alpha relapse.
Berg, Thomas, Hoffmann, Robert M., Hopf, Uwe, Lafrenz, Michael, Leifeld, Ludger, Pape, Gerd R., Spengler, Ulrich, Teuber, Gerlinde, Zeuzem, Stefan   +8 more
core   +1 more source

Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. [PDF]

, 2003
Roughly 50% of patients with chronic hepatitis C, who relapsed after a previous monotherapy with interferon alpha, will respond in a sustained fashion to 24 weeks of re-therapy with the combination of interferon alpha plus ribavirin.
August-Jörg, B.S., Borovicka, J., Dufour, J.F., Gonvers, J.J., Henz, S., Hermann, R., Meyenberger, C., Renner, E.L., Weitz, M.   +8 more
core   +1 more source

Liver-Targeting of Interferon-Alpha with Tissue-Specific Domain Antibodies [PDF]

, 2013
PMCID: PMC3581439This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
A Trahtenherts, A Walker, Adam Walker, AM Wu, Armin Sepp, B Saunier, C. Andrew Boswell, CL Van Broekhoven, Clare Mudd, DJ Peng, DY Yang, E Dieperink, Edward Coulstock, ES Ward, F Pacifico, G Dusheiko, Gráinne Dunlevy, Jane Sosabowski, Jerome Burnet, JH Park, Julie Foster, KA Deal, Laura Goodall, LC Platanias, LJ Holt, LJ Holt, M Abe, M Loignon, M Spiess, Marie Davies, Milan Ovečka, MW Fried, MW Fried, P Kallinteri, R Duncan, R Gay, R Iorio, Rob Prince, T Eto, U Iyer, U Treichel, WM Pardridge, XQ Zhang, Y Zhang, YI Jeong, YY Seow   +45 more
core   +3 more sources

Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]

, 2018
Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia, Boldeanu, Mihail V., Caragea, Daniel C., Ciurea, Marius E., Ciurea, Tudorel, Forțofoiu, Maria, Forțofoiu, Mircea C., Popescu-Drigă, Mircea, Pădureanu, Vlad, Rogoveanu, Ion, Streba, Costin, Săndulescu, Larisa, Vere, Cristin C.   +12 more
core   +3 more sources

Porcine innate and adaptative immune responses to influenza and coronavirus infections [PDF]

, 2006
Both innate and adaptative immune responses contribute to the control of infectious diseases, including by limiting the spreading of zoonotic diseases from animal reservoirs to humans.
Asselin-Paturel, Baudoux, BERNARD CHARLEY, Brim, Charley, Charley, Charley, Chen, Chinsangaram, Corthier, Fitzgerald-Bocarsly, Guzylack-Piriou, Heinen, KRISTIEN VAN REETH, La Bonnardière, Laude, Laude, Le Bon, Lim, Liu, Palese, Peiris, Pestka, Riffault, Riffault, Riffault, Rothenfusser, SABINE RIFFAULT, Saif, Siegal, Summerfield, Tu, Tudor, Van Reeth, Van Reeth, van Reeth   +35 more
core   +2 more sources

Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis [PDF]

, 2000
Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.
Amann, B., Grunze, Heinz, Loeschke, K., Schlösser, S., Schmidt, F., Schäfer, Martin   +5 more
core   +1 more source